Linezolid versus glycopeptides in the treatment of complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials

Zhifeng GUO,Zhiqing LIN,Ping HUANG,Qi CHEN

DOI: https://doi.org/10.16718/j.1009-7708.2011.04.013

2011-01-01

Abstract:A meta-analysis of randomized controlled trials was conducted to evaluate the efficacy and safety of linezolid versus glycopeptides in patients with complicated skin and soft tissue infections caused by gram-positive coccus. Methods The data were retrieved from the MEDLINE, EMBASE, OVID databases, the Cochrane library, and Chinese Biomedical Database. The references cited by eligible studies were manually screened. Randomized controlled trials published in English and Chinese comparing linezolid with glycopeptides in patients with complicated skin and soft tissue infections caused by gram-positive coccus were eligible for inclusion. Heterogeneity was examined by Chi-square test. Fixed effects model or random effects model was used to pool the data. Sensitivity analyses were conducted to verify the robustness of the results. Results Nine randomized controlled studies comparing linezolid with glycopeptides were analyzed, including 3 248 patients with complicated skin and soft tissue infections caused by gram-positive cocci. Meta-analysis showed that linezolid was more effective than glycopeptides in clinically evaluable patients in terms of clinical treatment success at the end-of-treatment visit [OP 1. 92, 95% CI (1. 18, 3. 14), P = 0. 009] and at the test-of-cure visit [OP 1. 59, 95% CI (1. 24, 2. 05), P = 0. 000 3]. However, there was no difference in intention-to-treat patients at the test-of-cure visit [OP 1. 37, 95% CI (0.98, 1.92), P = 0. 07]. With respect to microbiological treatment success, linezolid was more effective than glycopeptides in microbiologically evaluable patients at the test-of-cure visit [OP 1. 57, 95% CI 18, 2. 10), P - 0. 002]. Additionally, empirical treatment with linezolid was associated with higher eradication rates for S. aureus [OR = 2.34, 95% CI (1.63, 3.37), P<0. 000 01] and MRSA strains [OR = 2. 27, 95% CI (1.20, 4.31), P = 0.01] than glycopeptides in microbiologically evaluable patients at the test-of-cure visit. There was no difference between linezolid and glycopeptides in eradication rates for streptococcal species [OR =1.17, 95% CI (0. 23, 5. 97), P = 0. 85] and enterococcal species [OR = 6. 43, 95% CI (0. 23, 181. 82), P = 0. 28]. Conclusions Linezolid is more effective than glycopeptides for treatment of patients with complicated skin and soft tissue infections caused by gram-positive cocci although rigorously designed large sample size randomized double blind clinical trials are required to further demonstrate and support the conclusion.